PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1460745
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1460745
Chronic Pain Treatment Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)
Market Overview
The chronic pain treatment market achieved a revenue of USD 97.6 billion in 2023 and is projected to experience a compound annual growth rate (CAGR) of 7.4% from 2024 to 2030, reaching USD 159.6 billion by 2030. The major reasons accountable for the development of the industry include the growing government backing for these solutions, increasing elderly populace, and rising occurrence of chronic health conditions.
The industry players have been constantly spending in emerging innovative items for chronic pain treatment. Wearable tech for the treatment of long-lasting pain is one of the major improvements in the chronic pain treatment industry.
The World Health Organization projects a substantial surge in the worldwide populace aged 60 and more from 12% to 22% between 2015 and 2050. This demographic move has augmented the occurrence of chronic pain, mainly among elder patients in nursing homes, posing a challenge for care facilities.
To confront this problem, a combination of pharmacological, non-pharmacological (physical and occupational therapies), and occupational therapies is employed, positively impacting the chronic pain treatment market.
Chronic illnesses such as sickle-cell anemia, osteoarthritis, fibromyalgia, cancer, and autoimmune illnesses such as rheumatoid arthritis are dominant worldwide, requiring therapeutic interventions for better pain management. The extensive use of treatments such as physiotherapy, medication, and psychological therapy reflects the rising load of chronic diseases and their impact on healthcare systems globally.
Key Insights
The drugs category is projected to advance at a CAGR of around 7.7% and lead the industry share because of increasing chronic pain cases such as severe headaches, lower back pain, and facial pain.
Reasons contributing to this development include the growing worldwide elderly populace, sedentary lifestyles, and an increase in surgical procedures.
The need for painkillers is projected to intensify in response to these trends over the forecast period.
In 2023, the musculoskeletal category had a 40% industry share because of the high occurrence of musculoskeletal illnesses such as fibromyalgia, osteoarthritis, and rheumatoid arthritis.
In 2019-2021, as many as 53.2 million U.S. adults had these conditions: different kinds of arthritis (including rheumatoid arthritis), gout, lupus or fibromyalgia, according to NHIS (National Health Interview Survey).
Musculoskeletal segment is predicted to have a CAGR of 7.3% until the end of the forecast period due to some factors e.g. increase arthritis prevalence and back pain which is responsible for disability all over the world being at the top.
During the projection period, the cancer pain category is projected to advance at a CAGR of 8.0% based on indication.
The National Cancer Institute classifies cancer as a principal worldwide reason of death, with forecasts indicating increasing new cases and demises by 2040.
Growing cancer survivor numbers contribute to industry development because of the long-lasting and commonly severe pain related with the disease.
The APAC region is set to be the fastest-growing industry with a CAGR of 7.8% during the projection period, propelled by advancing healthcare infrastructure, increasing disposable income, rising elderly populace, and growing chronic pain prevalence.
Asia's elderly populace is projected to double from 395 million in 2019 to 587 million by 2030, paying to advanced demand for pain treatment medications and devices.
In 2023, the North American region, holding a 55% industry share, advantages from developed healthcare infrastructure, high healthcare spending, and extensive obtainability of advanced pain treatment solutions.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by product
- 1.4.2. Market size breakdown, by indication
- 1.4.3. Market size breakdown, by application
- 1.4.4. Market size breakdown, by distribution channel
- 1.4.5. Market size breakdown, by end user
- 1.4.6. Market size breakdown, by region
- 1.4.7. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Product (2017-2030)
- 6.3. Market Revenue, by Indication (2017-2030)
- 6.4. Market Revenue, by Application (2017-2030)
- 6.5. Market Revenue, by Distribution Channel (2017-2030)
- 6.6. Market Revenue, by End User (2017-2030)
- 6.7. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Product (2017-2030)
- 7.3. Market Revenue, by Indication (2017-2030)
- 7.4. Market Revenue, by Application (2017-2030)
- 7.5. Market Revenue, by Distribution Channel (2017-2030)
- 7.6. Market Revenue, by End User (2017-2030)
- 7.7. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Product (2017-2030)
- 8.3. Market Revenue, by Indication (2017-2030)
- 8.4. Market Revenue, by Application (2017-2030)
- 8.5. Market Revenue, by Distribution Channel (2017-2030)
- 8.6. Market Revenue, by End User (2017-2030)
- 8.7. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Product (2017-2030)
- 9.3. Market Revenue, by Indication (2017-2030)
- 9.4. Market Revenue, by Application (2017-2030)
- 9.5. Market Revenue, by Distribution Channel (2017-2030)
- 9.6. Market Revenue, by End User (2017-2030)
- 9.7. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Product (2017-2030)
- 10.3. Market Revenue, by Indication (2017-2030)
- 10.4. Market Revenue, by Application (2017-2030)
- 10.5. Market Revenue, by Distribution Channel (2017-2030)
- 10.6. Market Revenue, by End User (2017-2030)
- 10.7. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Product (2017-2030)
- 11.3. Market Revenue, by Indication (2017-2030)
- 11.4. Market Revenue, by Application (2017-2030)
- 11.5. Market Revenue, by Distribution Channel (2017-2030)
- 11.6. Market Revenue, by End User (2017-2030)
- 11.7. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Product (2017-2030)
- 12.3. Market Revenue, by Indication (2017-2030)
- 12.4. Market Revenue, by Application (2017-2030)
- 12.5. Market Revenue, by Distribution Channel (2017-2030)
- 12.6. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Product (2017-2030)
- 13.3. Market Revenue, by Indication (2017-2030)
- 13.4. Market Revenue, by Application (2017-2030)
- 13.5. Market Revenue, by Distribution Channel (2017-2030)
- 13.6. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Product (2017-2030)
- 14.3. Market Revenue, by Indication (2017-2030)
- 14.4. Market Revenue, by Application (2017-2030)
- 14.5. Market Revenue, by Distribution Channel (2017-2030)
- 14.6. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Product (2017-2030)
- 15.3. Market Revenue, by Indication (2017-2030)
- 15.4. Market Revenue, by Application (2017-2030)
- 15.5. Market Revenue, by Distribution Channel (2017-2030)
- 15.6. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Product (2017-2030)
- 16.3. Market Revenue, by Indication (2017-2030)
- 16.4. Market Revenue, by Application (2017-2030)
- 16.5. Market Revenue, by Distribution Channel (2017-2030)
- 16.6. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Product (2017-2030)
- 17.3. Market Revenue, by Indication (2017-2030)
- 17.4. Market Revenue, by Application (2017-2030)
- 17.5. Market Revenue, by Distribution Channel (2017-2030)
- 17.6. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Product (2017-2030)
- 18.3. Market Revenue, by Indication (2017-2030)
- 18.4. Market Revenue, by Application (2017-2030)
- 18.5. Market Revenue, by Distribution Channel (2017-2030)
- 18.6. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Product (2017-2030)
- 19.3. Market Revenue, by Indication (2017-2030)
- 19.4. Market Revenue, by Application (2017-2030)
- 19.5. Market Revenue, by Distribution Channel (2017-2030)
- 19.6. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Product (2017-2030)
- 20.3. Market Revenue, by Indication (2017-2030)
- 20.4. Market Revenue, by Application (2017-2030)
- 20.5. Market Revenue, by Distribution Channel (2017-2030)
- 20.6. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Product (2017-2030)
- 21.3. Market Revenue, by Indication (2017-2030)
- 21.4. Market Revenue, by Application (2017-2030)
- 21.5. Market Revenue, by Distribution Channel (2017-2030)
- 21.6. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Product (2017-2030)
- 22.3. Market Revenue, by Indication (2017-2030)
- 22.4. Market Revenue, by Application (2017-2030)
- 22.5. Market Revenue, by Distribution Channel (2017-2030)
- 22.6. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Product (2017-2030)
- 23.3. Market Revenue, by Indication (2017-2030)
- 23.4. Market Revenue, by Application (2017-2030)
- 23.5. Market Revenue, by Distribution Channel (2017-2030)
- 23.6. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Product (2017-2030)
- 24.3. Market Revenue, by Indication (2017-2030)
- 24.4. Market Revenue, by Application (2017-2030)
- 24.5. Market Revenue, by Distribution Channel (2017-2030)
- 24.6. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Product (2017-2030)
- 25.3. Market Revenue, by Indication (2017-2030)
- 25.4. Market Revenue, by Application (2017-2030)
- 25.5. Market Revenue, by Distribution Channel (2017-2030)
- 25.6. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Product (2017-2030)
- 26.3. Market Revenue, by Indication (2017-2030)
- 26.4. Market Revenue, by Application (2017-2030)
- 26.5. Market Revenue, by Distribution Channel (2017-2030)
- 26.6. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Product (2017-2030)
- 27.3. Market Revenue, by Indication (2017-2030)
- 27.4. Market Revenue, by Application (2017-2030)
- 27.5. Market Revenue, by Distribution Channel (2017-2030)
- 27.6. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Product (2017-2030)
- 28.3. Market Revenue, by Indication (2017-2030)
- 28.4. Market Revenue, by Application (2017-2030)
- 28.5. Market Revenue, by Distribution Channel (2017-2030)
- 28.6. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Eli Lilly and Company
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. GlaxoSmithKline plc
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Pfizer Inc.
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Medtronic plc
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Abbott Laboratories
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. Boston Scientific Corporation
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Novartis AG
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. Johnson & Johnson Services Inc.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. AstraZeneca PLC
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
- 30.10. Bristol-Myers Squibb Company
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary
- 30.11. Becton, Dickinson and Company
- 30.11.1. Business overview
- 30.11.2. Product and service offerings
- 30.11.3. Key financial summary
- 30.12. Sanofi S.A.
- 30.12.1. Business overview
- 30.12.2. Product and service offerings
- 30.12.3. Key financial summary
- 30.13. Teva Pharmaceutical Industries Limited
- 30.13.1. Business overview
- 30.13.2. Product and service offerings
- 30.13.3. Key financial summary
- 30.14. AbbVie Inc.
- 30.14.1. Business overview
- 30.14.2. Product and service offerings
- 30.14.3. Key financial summary
- 30.15. Paradigm Biopharmaceuticals Limited
- 30.15.1. Business overview
- 30.15.2. Product and service offerings
- 30.15.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
